Diffusion-weighted magnetic resonance imaging for evaluation of micro-angiogenesis in residual tumor after treatment with percutaneous ethanol injection in a rabbit VX2 liver tumor model

Chen Juan; Yin HuaBin; Zhang HuanHuan; Wei ChunXiao; Wang Li; Qian Ting

doi:10.3969/j.issn.1001-5256.2016.01.018

Volume 32 Issue 1

Jan. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(1): 101-105

PDF( 1812 KB)

Diffusion-weighted magnetic resonance imaging for evaluation of micro-angiogenesis in residual tumor after treatment with percutaneous ethanol injection in a rabbit VX2 liver tumor model

DOI: 10.3969/j.issn.1001-5256.2016.01.018

Department of Radiology,Shanghai Fifth People's Hospital Affiliated to Fudan University

Research funding:

Received Date: 2015-08-24
Published Date: 2016-01-20

Abstract

Abstract

Objective To investigate the application of diffusion- weighted magnetic resonance imaging( DW- MRI) for the evaluation of the therapeutic effect of percutaneous ethanol injection( PEI) and its effect on micro- angiogenesis in residual tumor in a rabbit VX2 liver tumor model. Methods A total of 26 rabbits with VX2 liver tumor were randomly divided into experimental group and control group,with13 rabbits in each group. CT- guided PEI was performed for the experimental group,and no treatment was performed for the control group.DW- MRI was performed at 1 week after operation. Apparent diffusion coefficient( ADC) ADCtotalin the active tumor areas and necrosis areas were compared within the experimental group,ADCperfand microvascular density( MVD) count in the active tumor areas were compared between the two groups,and the correlation between ADCperfand MVD count was analyzed. The Shapiro- Wilk test was applied for normality analysis,the Wilcoxon rank sum test was applied for comparison of continuous data between the two groups,and the correlation between ADCperfand MVD count was analyzed by the Pearson correlation coefficient. Results In the experimental group,ADCtotalshowed a significant difference between the necrosis areas and the active tumor areas( [1. 674( 1. 340- 2. 571) ] × 10- 3mm2/ s vs [1. 296( 1. 120-1. 972) ]× 10- 3mm2/ s; Z = 2. 052,P = 0. 040). ADCperfand MDV count in the active tumor areas showed no significant differences between the experimental group and the control group [0. 568( 0. 381- 1. 873) ]× 10- 3mm2/ s vs [0. 947( 0. 518- 1. 476) ]× 10- 3mm2/ s,Z =0. 487,P = 0. 626; 23. 641 ± 6. 138 vs 23. 487 ± 3. 466; Z =- 0. 128,P = 0. 898). In both groups,ADCperfin the active tumor areas was positively correlated with MDV count( r = 0. 583 and 0. 593,P = 0. 037 and 0. 033). Conclusion DW- MRI can accurately assess the therapeutic effect of PEI and reflect the condition of micro- angiogenesis in a rabbit VX2 liver tumor model. At 1 week after PEI,PEI has no obvious effect on micro- angiogenesis in residual tumor.
- liver neoplasms,
- diffusion magnetic resonance imaging,
- catheter ablation,
- models,animal

FullText(HTML)

References(19)

References

[1]AGNELLO F,SALVAGGIO G,CABIBBO G,et al.Imaging appearance of treated hepatocellular carcinoma[J].World J Hepatol,2013,5(8):417-424.

[2]ZHU XM,WU F,ZHANG YW.Clinical application of functional imaging in estimating the efficacy of interventional treatment of hepatocellular carcinoma[J].Contemp Medicine,2010,16(29):621-623.(in Chinese)朱晓明,吴非,张跃伟.肝癌介入治疗疗效的功能影像学评估[J].当代医学,2010,16(29):621-623.

[3]LIN JW,LIN CC,CHEN WT,et al.Combining radiofrequency ablation and ethanol injection may achieve comparable long-term outcomes in larger hepatocellular carcinoma(3.1-4 cm)and in high-risk locations[J].Kaohsiung J Med Sci,2014,30(8):396-401.

[4]QIAN T,CHEN MZ,GAO F,et al.Comparison of two methods used in establishing VX-2 liver tumor model in rabbits and their imaging evaluation[J].J Intervent Radiol,2014,23(1):58-61.(in Chinese)钱亭,陈茂振,高峰,等.两种方法建立兔VX2肝癌模型的比较及影像学评估[J].介入放射学杂志,2014,23(1):58-61.

[5]LI B,CHEN H,WU MC,et al.Ultrasound-guided liver biopsy and intratumor injection of anhydrous alcohol in treatment of liver cancer:a clinical analysis of 188 cases[J].Chin J Pract Surg,1996,16(2):84-85.(in Chinese)李波,陈汉,吴孟超,等.超声引导肝脏穿刺瘤内注射无水酒精治疗肝癌(附188例临床分析)[J].中国实用外科杂志,1996,16(2):84-85.

[6]WANG H,LI J,CHEN F,et al.Morphological,functional and metabolic imaging biomarkers:assessment of vascular-disrupting effect on rodent liver tumours[J].Eur Radiol,2010,20(8):2013-2026.

[7]WEIDNER N.Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors[J].Breast Cancer Res Treat,1995,36(2):169-180.

[8]YUAN YH,XIAO EH,WANG KY,et al.Study on the dynamic characteristics and pathological mechanism of magnatic resonance diffusion weighted imaging after chemoembolizaiton in rabbit liver VX-2 tumor model[J].J Chin Physician,2012,14(9):1165-1170.(in Chinese)袁友红,肖恩华,王柯懿,等.兔肝VX-2瘤化疗栓塞前后磁共振扩散成像的动态特征及病理机制[J].中国医师杂志,2012,14(9):1165-1170.

[9]CHANDARANA H,TAOULI B.Diffusion and perfusion imaging of the liver[J].Eur J Radiol,2010,76(3):348-358.

[10]SUH YJ,KIM MJ,CHOI JY,et al.Preoperative prediction of the microvascular invasion of hepatocellular carcinoma with diffusionweighted imaging[J].Liver Transpl,2012,18(10):1171-1178.

[11]NAKANISHI M,CHUMA M,HIGE S,et al.Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma[J].Ann Surg Oncol,2012,19(4):1302-1309.

[12]THOENY HC,de KEYZER F,VANDECAVEYE V,et al.Effect of vascular targeting agent in rat tumor model:dynamic contrast-enhanced versus diffusion-weighted MR imaging[J].Radiology,2005,237(2):492-499.

[13]LAN WS,HU DY,LI Z,et al.Diffusion weighted imaging for evaluation of therapeutic efficiency of percutaneous ethanol injection of rabbit soft tissue VX2 tumor[J].Radiol Pract,2013,28(8):825-828.(in Chinese)兰为顺,胡道予,李震,等.DWI评价无水乙醇注射治疗兔软组织VX2肿瘤疗效[J].放射学实践,2013,28(8):825-828.

[14]KAMEL IR,LIAPI E,REYES DK,et al.Unresectable hepatocellular carcinoma:serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging[J].Radiology,2009,250(2):466-473.

[15]LIU YB,LIANG CH,WANG QS,et al.3.0 T MR diffusion weighted imaging in the evaluation of radio-frequency ablation of the liver VX2 tumors[J].Chin J Radiol,2010,44(12):1324-1328.(in Chinese)刘于宝,梁长虹,王秋实,等.3.0 T MR扩散加权成像评价兔肝VX2瘤射频消融治疗的实验研究[J].中华放射学杂志,2010,44(12):1324-1328.

[16]SHAO H,NI Y,ZHANG J,et al.Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors[J].PLo S One,2013,8(12):e82649.

[17]FOLKMAN J.Role of angiogenesis in tumor growth and metastasis[J].Semin Oncol,2002,29(6 Suppl 16):15-18.

[18]IAGARU A,GAMBHIR SS.Imaging tumor angiogenesis:the road to clinical utility[J].AJR Am J Roentgenol,2013,201(2):w183-w191.

[19]QIAN T,CHEN M,GAO F,et al.Diffusion-weighted magnetic resonance imaging to evaluate microvascular density after transarterial embolization ablation in a rabbit VX2 liver tumor model[J].Magn Reson Imaging,2014,32(8):1052-1057.

Relative Articles

[1]	Wei YAN, Huifang HUANG. Effect of glucocorticoid in the treatment of severe drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(10): 2302-2307. doi: 10.3969/j.issn.1001-5256.2022.10.019
[3]	Yu HE, Jidong JIA, Ping WANG. Research advances in the role of the glucocorticoid-induced tumor necrosis factor receptor-related protein and its ligand in liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(7): 1718-1723. doi: 10.3969/j.issn.1001-5256.2021.07.051
[4]	Long LIU, Yao LIU, Fangyuan GAO, Xianbo WANG. Clinical features of chronic liver disease with autoimmune blood diseases and the clinical effect of glucocorticoid[J]. Journal of Clinical Hepatology, 2021, 37(8): 1878-1882. doi: 10.3969/j.issn.1001-5256.2021.08.025
[5]	Yang Jun, Hu ZhongJie, Zhu YueKe, Yu HongWei, Li Juan, Hou Wei, Ning QiQi. Clinical effect of glucocorticoids versus pentoxifylline in patients with severe alcoholic liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(7): 1546-1550. doi: 10.3969/j.issn.1001-5256.2019.07.025
[6]	Zhao YouYou, Zhang Duan, Yin Xin, Wen XiaoYu, Gao PuJun. Glucocorticoid treatment of intrahepatic cholestasis caused by infectious cholangitis: A case report[J]. Journal of Clinical Hepatology, 2019, 35(2): 386-387. doi: 10.3969/j.issn.1001-5256.2019.02.031
[7]	Ma Juan, Liu YuLan. Corticosteroid therapy for autoimmune pancreatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1599-1603. doi: 10.3969/j.issn.1001-5256.2018.08.002
[9]	Wang XiuFang, Feng GuoHe. Research advances in glucocorticoids for the treatment of liver failure[J]. Journal of Clinical Hepatology, 2018, 34(7): 1565-1568. doi: 10.3969/j.issn.1001-5256.2018.07.043
[10]	Meng QingHua. Timing of glucocorticoid therapy for liver failure[J]. Journal of Clinical Hepatology, 2017, 33(9): 1683-1686. doi: 10.3969/j.issn.1001-5256.2017.09.011
[11]	Liu LiBin, Wang Min, Tian YueLi, Cong Jing, Wang LiYing. Severe fatty liver induced by glucocorticoids: a report of one case[J]. Journal of Clinical Hepatology, 2016, 32(1): 161-162. doi: 10.3969/j.issn.1001-5256.2016.01.034
[12]	Qiu Bo, Zhu Ling, Wang TangMing, Yan ShiChun, Zhang JianMing, Xie ZhiAn, Liu XingYu. Efficacy of low-dose glucocorticoids in treatment of HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2016, 32(7): 1300-1304. doi: 10.3969/j.issn.1001-5256.2016.07.017
[13]	Chang BinXia, Teng GuangJu, Sun Ying, Zhao Jun, Zhang Wei, Zou ZhengSheng, Li BaoSen. Drug-induced liver injury caused by treatment of complications after glucocorticoid therapy for panniculitis: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(5): 775-776. doi: 10.3969/j.issn.1001-5256.2015.05.035
[14]	Ge HongYan, Wang YingShu. Clinical efficacy of glucocorticoid therapy in treatment of drug-induced cholestatic liver disease[J]. Journal of Clinical Hepatology, 2015, 31(10): 1618-1620. doi: 10.3969/j.issn.1001-5256.2015.10.014
[15]	Zhou XinMin, Dong XuYang. Therapeutic strategies of liver failure for clinical cases[J]. Journal of Clinical Hepatology, 2012, 28(2): 93-98.
[16]	Wang Meng, Nie QingHe. Meta-analysis of the efficacy and complications of glucocorticoids in patients with severe hepatitis-related liver failure [J]. Journal of Clinical Hepatology, 2012, 28(10): 764-770.
[17]	Zhou XianShan, Wan MoBin, Xue JianYa, Zhang Bin. Effects of glucocorticoids combined with antiviral therapy in treatment of patients with chronic severe hepatitis B.[J]. Journal of Clinical Hepatology, 2008, 24(2): 101-103.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	朱惠刚，刘东升，贾楷桥. 腹腔镜下精准肝切除术与常规腹腔镜肝肿瘤切除术治疗原发性肝癌的效果及安全性. 中西医结合肝病杂志. 2022(07): 648-650 .
2.	邓明，邓芳，陈志坚，周福生. 连翘苷对胃癌细胞AGS增殖、迁移和侵袭的抑制作用. 中成药. 2022(09): 3009-3012 .
3.	赵金磊，季春勇，石伟，罗红杰，季予江，刘东亮. 长链非编码RNA MIAT在肝细胞癌组织中的表达及临床意义. 临床肿瘤学杂志. 2021(03): 217-221 .
4.	侯亚萍，张小晶，李婷. 原发性肝癌患者LncRNA-MEG3表达与临床病理特征及预后的关系. 肝脏. 2021(07): 757-760 .
5.	陈绪林，姜宇，赵艳，李彩华，高逸之. 原发性肝癌组织中miR-557的表达及其与预后的关系. 国际消化病杂志. 2021(04): 313-316 .
6.	杜小梅，吕建宁，李雯. 长链非编码RNA EXOC7在非小细胞肺癌中的表达及临床意义分析. 临床肺科杂志. 2020(04): 592-595 .
7.	林洁，黄炳臣，王娟，黄云美，黄小英. 肝癌患者组织及血清微小RNA-24和微小RNA-629的表达水平及其临床意义. 广西医学. 2020(14): 1775-1778 .
8.	梅洪亮，黄致远，胡逸林，江艳，陈敏，卢绮萍，刘志苏. 长链非编码RNA KCNQ1重叠转录物1在肝细胞癌迁移及增殖和侵袭中的作用与机制研究. 中华消化外科杂志. 2020(10): 1083-1090 .
9.	杨书才，张莉，刘利平，邓唯杰，周杰，刘慧，张鲍虎，金涛. 缺氧诱导因子2α对肝细胞癌化疗耐药性的影响. 中国临床药理学与治疗学. 2019(06): 630-636 .
10.	钟蓝海，马丹丹，张智勇，张翌，蔡逊. 基于数据挖掘分析FAM134B在肝癌中的表达及其与预后的关系. 临床肝胆病杂志. 2019(11): 2508-2512 . 本站查看
11.	唐丽，唐华，孙强. FOXM1、FOXO3a在肝癌中的表达及其临床意义. 临床医学研究与实践. 2019(36): 24-26 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2440) PDF downloads(439)

Diffusion-weighted magnetic resonance imaging for evaluation of micro-angiogenesis in residual tumor after treatment with percutaneous ethanol injection in a rabbit VX2 liver tumor model

DOI: 10.3969/j.issn.1001-5256.2016.01.018